Myriad Genetics, Inc. (MYGN): Price and Financial Metrics


Myriad Genetics, Inc. (MYGN)

Today's Latest Price: $13.99 USD

0.36 (-2.51%)

Updated Oct 28 10:06am

Add MYGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

MYGN Stock Summary

  • MYGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.29 -- higher than merely 14.39% of US-listed equities with positive expected earnings growth.
  • In terms of twelve month growth in earnings before interest and taxes, Myriad Genetics Inc is reporting a growth rate of -1,840.98%; that's higher than only 0.93% of US stocks.
  • As for revenue growth, note that MYGN's revenue has grown -24.97% over the past 12 months; that beats the revenue growth of only 11.58% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Myriad Genetics Inc are OFIX, MMSI, ENZ, RFL, and IOSP.
  • Visit MYGN's SEC page to see the company's official filings. To visit the company's web site, go to myriad.com.

MYGN Stock Price Chart Interactive Chart >

Price chart for MYGN

MYGN Price/Volume Stats

Current price $13.99 52-week high $35.29
Prev. close $14.35 52-week low $9.24
Day low $13.91 Volume 28,858
Day high $14.35 Avg. volume 999,673
50-day MA $13.33 Dividend yield N/A
200-day MA $15.16 Market Cap 1.05B

Myriad Genetics, Inc. (MYGN) Company Bio


Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.

MYGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$13.99$2.19 -85%

Below please find a table outlining a discounted cash flow forecast for MYGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Myriad Genetics Inc ranked in the 14th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 84.67%. The most interesting components of our discounted cash flow analysis for Myriad Genetics Inc ended up being:

  • Its compound free cash flow growth rate, as measured over the past 5.53 years, is -0.1% -- higher than merely 14.8% of stocks in our DCF forecasting set.
  • Myriad Genetics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -19.67. This coverage rate is greater than that of just 5.59% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 11. This value is greater than 83.24% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-85%
1%-85%
2%-85%
3%-85%
4%-84%
5%-84%

Want more companies with a valuation profile/forecast similar to that of Myriad Genetics Inc? See IDXX, LMNX, BSX, ELAN, and NUVA.


MYGN Latest News Stream


Event/Time News Detail
Loading, please wait...

MYGN Latest Social Stream


Loading social stream, please wait...

View Full MYGN Social Stream

Latest MYGN News From Around the Web

Below are the latest news stories about Myriad Genetics Inc that investors may wish to consider to help them evaluate MYGN as an investment opportunity.

Myriad Genetics (MYGN) Q4 2020 Results - Earnings Call Transcript

Myriad Genetics, Inc. (MYGN)Q4 2020 Earnings CallAugust 13, 2020 4:30 pm ETExecutivesScott Gleason - Myriad Genetics, Inc.R. Bryan Riggsbee - Myriad Genetics, Inc.Paul J. Diaz - Myriad Genetics, Inc.AnalystsSung-Ji Nam - BTIG LLCDoug Schenkel - Cowen and Company, LLCTycho W. Peterson - JPMorgan Securities LLCStephen Unger - Needham & Co....

SA Transcripts on Seeking Alpha | August 14, 2020

Myriad Genetics, Inc. 2020 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Myriad Genetics, Inc. in conjunction with their 2020 Q4 earnings call....

SA Transcripts on Seeking Alpha | August 14, 2020

Myriad Genetics Announces Inducement Awards

SALT LAKE CITY, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular…

GlobeNewswire | August 14, 2020

Global Genomics Market Outlook 2020-2025; Dominated by Illumina, Thermo Fisher Scientific, Agilent Technologies, Luminex Corporation and Myriad Genetics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Genomics Market - Growth, Trends, and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering. The Global Genomics Market is anticipated to grow at a CAGR of 9.3% during the forecast period. The major factors attributing to the growth of the genomics market are growing government support and increased number of genomics studies, declining sequencing cost, increased genomics applications. The genomics market is geared to exponential growth

Business Wire | August 13, 2020

Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

SALT LAKE CITY, July 31, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis® CDx for men with prostate cancer who are eligible or may become eligible for treatment Lynparza® (olaparib). BRACAnalysis CDx is the only germline test covered for this indication. “One in six patients with prostate cancer have a hereditary form of the disease and are six times more likely to die from it within five years,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Providers with earlier knowledge of their patient’s germline status can help tailor treatments and can provide eligibility for life-sustaining therapies should they pro...

Yahoo | July 31, 2020

Read More 'MYGN' Stories Here

MYGN Price Returns

1-mo 10.51%
3-mo 14.95%
6-mo -5.47%
1-year -57.82%
3-year -59.87%
5-year -65.35%
YTD -48.62%
2019 -6.33%
2018 -15.36%
2017 106.03%
2016 -61.38%
2015 26.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8252 seconds.